

IMMUNOGEN INC
Form 4
April 17, 2007

FORM 4

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
BLATTLER WALTER

(Last) (First) (Middle)

**C/O IMMUNOGEN, INC., 128
SIDNEY STREET**

(Street)

CAMBRIDGE, MA 02139

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
IMMUNOGEN INC [IMGN]

3. Date of Earliest Transaction
(Month/Day/Year)
04/13/2007

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

____ Director
____ Officer (give title below) Other (specify below)
Executive Vice President / Former Executive VP

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
 Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
			Code	V	Amount or Price (A) or (D)		
Common Stock	04/13/2007		S		6,400	D	
Common Stock	04/13/2007		S		3,650	D	
Common Stock	04/13/2007		S		4,999	D	
Common Stock	04/13/2007		S		16,935	D	
Common Stock	04/13/2007		S		21,133	D	

Edgar Filing: IMMUNOGEN INC - Form 4

Common Stock	04/13/2007	S	32,292	D	\$ 5.6	230,851	D
Common Stock	04/13/2007	S	9,545	D	\$ 5.61	221,306	D
Common Stock	04/13/2007	S	8,260	D	\$ 5.62	213,046	D
Common Stock	04/13/2007	S	9,838	D	\$ 5.63	203,208	D
Common Stock	04/13/2007	S	7,159	D	\$ 5.64	196,049	D
Common Stock	04/13/2007	S	4,073	D	\$ 5.65	191,976	D
Common Stock	04/13/2007	S	900	D	\$ 5.66	191,076	D
Common Stock	04/13/2007	S	1,900	D	\$ 5.67	189,176	D
Common Stock	04/13/2007	S	3,300	D	\$ 5.69	185,876	D
Common Stock	04/13/2007	S	2,600	D	\$ 5.7	183,276	D
Common Stock	04/13/2007	S	3,517	D	\$ 5.76	179,759	D
Common Stock	04/13/2007	S	4,971	D	\$ 5.77	174,788	D
Common Stock	04/13/2007	S	1,188	D	\$ 5.78	173,600	D
Common Stock	04/13/2007	S	5,200	D	\$ 5.79	168,400	D
Common Stock	04/13/2007	S	2,700	D	\$ 5.8	165,700	D
Common Stock	04/13/2007	S	1,642	D	\$ 5.81	164,058	D
Common Stock	04/13/2007	S	4,251	D	\$ 5.82	159,807	D
Common Stock	04/13/2007	S	7,807	D	\$ 5.83	152,000	D
Common Stock	04/13/2007	S	600	D	\$ 5.84	151,400	D
Common Stock	04/13/2007	S	200	D	\$ 5.85	151,200	D
	04/13/2007	S	2,300	D		148,900	D

Edgar Filing: IMMUNOGEN INC - Form 4

Common Stock					\$				
					5.86				
Common Stock	04/13/2007		S	500	D	\$	148,400	D	
						5.87			

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Owned Following Reporting Transaction (Instr. 6)
--------------------------------------------	--------------------------------------------------------	--------------------------------------	----------------------------------------------------	--------------------------------	-----------------------------------------------------------------------------------------	----------------------------------------------------------	---------------------------------------------------------------	--------------------------------------------	-------------------------------------------------------------------------------------

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
BLATTLER WALTER C/O IMMUNOGEN, INC. 128 SIDNEY STREET CAMBRIDGE, MA 02139			Executive Vice President	Former Executive VP

Signatures

/s/ Walter Blattler
Date: 04/17/2007

**Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
 - ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Edgar Filing: IMMUNOGEN INC - Form 4

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.